吉西他滨联合希罗达治疗晚期胰腺癌的疗效比较

目的：观察吉西他滨联合希罗达治疗晚期胰腺癌的疗效和不良反应。方法：对50例晚期胰腺癌患者给予此方案化疗4个周期,按WHO标准评定疗效及不良反应,同时综合评估临床受益率指标：疼痛、体力状况及体重变化。结果：客观有效率为42.9%,中位生存时间为7.4个月,1年生存率为32%。主要不良反应为血液学毒性和脱发。结论：吉西他滨加希罗达是治疗晚期胰腺癌的一种安全有效的化疗方案,有较高的肿瘤缓解率,毒性较低,值得在临床上进一步推广应用。

Evaluation of the Clinical Efficacy of Chemotherapy with Gemcitabine and Capecitabine in Treatment of Advanced Pancreatic Cancer

Objective：To evaluate the efficacy and toxicity of combination therapy with gemcitabine and capecitabine in advanced pancreatic carcinoma.Method：50 patients was treated with this regimen for 4 cycles.The efficacy and side effect were evaluated according to the WHO criterion,and the indexes of CBR including ache,physical strength and body weight were also evaluated.Result：The objective response rate was 42.9%,the media survival time was 7.4 months,survival rate of one year was 53.8%.The main adverse reactions had hematologic toxicity and hair loss.Conclusion：Gemcitabine combined with capecitabine for treatment of advanced pancreatic cancer may obtain high response rate and comparatively low toxicity.This is a kind of effective and safe regimen of chemotherapy.May obtain high response rate and comparatively low toxicity.